Status Report Euro-BioImaging - J Ellenberg S Schönberg Report Euro... · Euro)BioImaging!Hub!...
Transcript of Status Report Euro-BioImaging - J Ellenberg S Schönberg Report Euro... · Euro)BioImaging!Hub!...
Euro-‐BioImaging
4th Stakeholder Mee7ng January 21-‐22, ACV Vienna
Jan Ellenberg and Stefan Schönberg Euro-‐BioImaging Scien9fic Coordinators
Participate in the Revolution in Bioimaging Technologies
Participate in the Revolution in Bioimaging Technologies
Strong Pan-European Support
250 Euro-‐BioImaging Partners from 28 countries
Na9onal investment made or planned, EuBI on roadmap
in 12 countries
39 Legal Partners, 250 Associated Partners from 28 Countries, > 270 Letters of Intent , > 1400 Stakeholders
19 na9onal imaging communi9es formed in
Key added values of a European RI
Why should European countries invest into and run a European distributed research infrastructure for biological and medical imaging?
No single European country can run cuBng-‐edge facili9es for all exis9ng and new imaging technologies: 1. By coordina9ng and integra9ng its efforts, Europe can achieve and maintain
leadership in imaging technologies in the global research landscape.
2. A pan-‐European commitment to imaging infrastructure will provide long-‐term sustainability for research infrastructure in imaging technologies.
3. Na9onal scien9sts will gain open access to all relevant imaging technologies they need in partner countries delivered by the best experts in the field.
National Imaging Initiatives in 19 countries
National Imaging Initiatives in 19 countries
e.g.
...
National Imaging Infrastructure with Open Access for national users
Examples of exis9ng and planned na7onal research infrastructures
Nodes of European significance. AMrac9ve and open for transna9onal access.
National Contribution to European research infrastructure
Mul9modal Technology Nodes
Single Technology Flagship Nodes
Euro-‐BioImaging Hub
Distributed research infrastructure model for Euro-BioImaging
MULTIMODAL TECHNOLOGY NODES provide excellence by integra9on of mul9ple imaging technologies at one site TE
CHNOLO
GY NODE
S
WITH OPEN USER AC
CESS
SINGLE TECHNOLOGY FLAGSHIPS offer an innova9ve technology at European leading level
Euro-‐BioImaging HUB (Responsibili9es: coordina9on & support, access, data, training;
Executes board decisions e.g. evalua9on, upgrade decommissioning; external representa9on)
Na9onal imaging infrastructure e.g. France-‐BioImaging, GEBI, …
EURO
-‐BIOIM
AGING IN
FRASTRUCTU
RE
> 19 COORDINATED NATIONAL IMAGING INITIATIVES
Operational Model
MULTIMODAL TECHNOLOGY
NODE
Imaging Infrastructure with physical open user access
FLAG
SHIP NODE
FLAG
SHIP NODE
FLAG
SHIP NODE
FLAG
SHIP NODE
USER TR
AINING STAFF TRAIN
ING
Web-‐access portal
European life scien9sts as users
Data storage and analysis infrastructure
User goes home with results for publica9on
HUB
NODE
S MULTIMODAL TECHNOLOGY
NODE
Testing the Infrastructure Model: Proof-of-Concept Studies
Major results • Euro-BioImaging received 228 user applications from 23 European countries,
as well as USA, Australia, and Singapore. • More than 110 users visited 51 imaging facilities in 14 European countries
from January to July 2012.
• In total, more than 60% of all users applied for transnational access, 89% left their home town for getting access.
Proof-of-Concept Studies
Imaging technologies tested for open and transna7onal user access
PCS Results
38
3
13
5
28
2
0
7
6
5
2
0
0
0 5 10 15 20 25 30 35 40
WP6 Mul9-‐modal integrated ALM
WP7-‐ CLEM
WP7-‐ Func9onal Imaging
WP7-‐ High-‐throughput
WP7-‐ Super Resolu9on
WP8-‐ Mesoscopic Imaging
WP8-‐ Probes ALM
WP8-‐ Mul9-‐Modal Molecular Imaging
WP8-‐ Probes MI
WP9-‐ HF-‐MRI
WP9-‐ PCI
WP10-‐ Image guided Therapy
WP10-‐ Popula9on
Number of user access based on PCS survey
17
2
2
2
1
4
3
4
3
3
Number of visited facili9es
Imaging technologies tested for open and transna7onal user access
PCS Results
38
3
13
5
28
2
0
7
6
5
2
0
0
0 5 10 15 20 25 30 35 40
WP6 Mul9-‐modal integrated ALM
WP7-‐ CLEM
WP7-‐ Func9onal Imaging
WP7-‐ High-‐throughput
WP7-‐ Super Resolu9on
WP8-‐ Mesoscopic Imaging
WP8-‐ Probes ALM
WP8-‐ Mul9-‐Modal Molecular Imaging
WP8-‐ Probes MI
WP9-‐ HF-‐MRI
WP9-‐ PCI
WP10-‐ Image guided Therapy
WP10-‐ Popula9on
Number of user access based on PCS survey
17
2
2
2
1
4
3
4
3
3
Number of visited facili9es
Changing the European Infrastructure Landscape
Collaboration Framework Agreement between Euro-BioImaging and AMMRF
Jan Ellenberg (Scientific Coordinator, Euro-BioImaging) and Simon Ringer (Executive Director, AMMRF), after signing the collaboration framework agreement. EMBL Heidelberg, Feb 1st, 2012
International relations: Australia
Collaboration Framework Agreement between Euro-BioImaging and India BioImaging in preparation
International relations: India
INDIA BioImaging
Jan Ellenberg and Antje Keppler (Euro-BioImaging) at the inauguration of INDIA BioImaging. NCBS Bangalore, Sep 21st, 2012
“This experience has given novel stimuli to my studies. Furthermore, I have set the bases for future experiments developed in collaboration with the Advanced Light Microscopy Facility. I thank the Euro-BioImaging initiative for having given me this opportunity.” (I.A. Asteriti)
Italia Anna Asteri7, CNR -‐ Ins9tute of Molecular Biology and Pathology, Rome, Italy. Visited the Advanced Light Microscopy Facility of the EMBL (Heidelberg)
Used technology High throughput microscopy Results A large number of data, assaying within the same experiment several doses of the Aurora-‐A inhibitor and prolonging the observa9on over long 9mes, were acquired. The obtained results will be likely to contribute to the understanding of the mito9c roles of Aurora-‐A, as well as to a future ra9onalisa9on of the use of Aurora-‐A inhibitors in cancer therapy.
Biological Imaging PCS study (1 of 89): From cell biology to cancer therapy: a high-throughput microscopy approach for the study of Aurora-A inhibition in human cells
U2OS cells pre-‐synchronised at the G1/S transi9on (snapshot from a movie).
Petra Kolenc Peitl, University Medical Centre Ljubljana, Slovenia Visited the Radboud University Nijmegen Medical Centre
Used technology SPECT/CT Results The study allowed the quantification of radionucleotide-labeled peptides in the kidneys providing new insights on how to improve kidney protection in peptide receptor radionuclide therapy in the future.
Molecular imaging PCS study (1 of 13): Stereochemistry of amminoacid spacers determines the pharmacokinetics of 111In-DOTA-minigastrin analogs for targeting of the gastrin receptor
Comparison of kidney reten9on of two In-‐111 labeled minigastrin analogues.
“I found really inspiring that I was never just an observer but I was an ac9ve actor from the beginning to the end, having the possibility to work with a small animal-‐dedicated SPECT/CT machine. There was always technical support available from nice and very well skilled people. This concept of work makes the interpreta9on of the final results much easier since you are aware of the cri9cal points in each individual step that leads to the final result.”
Karsten Specht, University of Bergen, Norway Visited the Leibniz-‐Ins7tute for Neurobiology, Magdeburg, Germany
Results The results are indica9ng a differen9al func9onal asymmetry of the different phone9c aspects, i.e. the lej and the right auditory system responds differently to them. This gives further evidence to current models on the func9onal asymmetry of speech percep9on and helps further iden9fying the informa9on flow in the brain.
Medical Imaging PCS study (1 of 7): Information integration, transcallosal communication, and inter-individual variability during the processing of voiced and unvoiced consonants in speech signals
Used technology: 7T MR scanner
“The en9re process around the Euro-‐BioImaging PCS studies was very smooth and s9mula9ng. It was a unique opportunity to conduct a study that could complement my earlier studies. “ (K. Specht)
Major results – Imaging facility perspective • The staff efforts for user management, sample-preparation and hands-on user
training were much higher in most cases than anticipated.
• For providing external access in the future, additional staff is needed.
• The average duration of the user visit lasted 2 weeks.
• 97% of the participating facilities would offer open access in the future after capacity upgrade.
Proof-of-Concept Studies
Major results – User perspective
• All users rate the Euro-BioImaging PCS access policy (central online application, communication, transparency, time until access) to be very good to excellent.
• >70% of users rate the validity of the obtained results to be very good to excellent for publication.
• >90% state that the benefit of the PCS was worth the effort of traveling.
• 99% of users would make use of Euro-BioImaging open access facilities in the future.
Proof-of-Concept Studies
The Euro-BioImaging infrastructure model is requested by users and works
• 97% of the facilities would offer open access after capacity upgrade.
• 99% of the users would use of Euro-BioImaging open access facilities.
• Over 60% transnational access, 89% of users left their home town.
2012 2013 2014
From Planning to Construction
Criteria for nodes
Governance & Legal
Structure
Survey PCS Natl. Communi7es
Infrastructure model for each
imaging technology
Tech
nica
l WP
s
Stra
tegi
c W
Ps
Finance Plan
✔
✔
Business plan
Open Call for EuBI Nodes
Negotiation with Member States = EuBI Partners
Euro-BioImaging Infrastructure
construction operation
1st Open Call for Euro-‐BioImaging Nodes – Expressions of Interest
How to become a EuBI Node
1st Open Call
Euro-BioImaging Nodes – Expression of Interest
The 1st Open Call runs from 25 January – 30 April 2013
Focuses on nodes that provide physical open access to imaging technologies that have demonstrated feasability by e.g. PCS
Imaging technologies that were successfully evaluated in PCS:
Multi-modal Advanced Light Microscopy Correlative Light-Electron Microscopy Functional Imaging Super Resolution Microscopy High-throughput Microscopy Mesoscopic Imaging Multi-Modal Molecular Imaging Probes-Molecular Imaging Phase contrast Imaging High-field MRI MRI-PET (evaluated by alternative proof-of-feasibility)
Eligibility
• Applicant demonstrates the user need for new capacity (LeMers of Intent from 50% of external users but max. 30 leMers)
• Applicant guarantees to provide open access for Euro-‐BioImaging users to at least 50 % of new capacity (comprises instrument 9me, staff capacity, storage capacity, …)
• Applicant demonstrates exis9ng communica7on with na7onal/regional funders for infrastructure capacity upgrade
• The applicant demonstrates that the single-‐sited or mul9-‐sited Node will cons9tute a legal en7ty, which in its en9rety will become part of Euro-‐BioImaging and as such a legal contractual partner of Euro-‐BioImaging
• Applicants from ESFRI Countries are eligible.
General Review
General Review Criteria
The following General Review Criteria should be addressed in each Expression of Interest: • Scientific and technical excellence of the infrastructure Node • Quality and scientific field of the academic environment • Geographic coverage • Maintenance and update • European and national significance • Access and service package • Use and quality assurance • User training • If applicable, evidence of funding commitment by national funders
Technology Specific Review
Common Technology Review Criteria
Technology Specific Review
Specific Technology Review Criteria – Example: High-throughput Microscopy
• Large-‐scale reagent libraries for cell or organism perturba9ons (e.g. siRNA , cDNA or chemical libraries)
• Support in assay development and adapta9on of low throughput laboratory assays to automa9on
• Support in high-‐throughput sample prepara9on (e.g. cell seeding devices, liquid handling, robots)
• High-‐throughput image acquisi9on technology and live cell imaging • Support in large-‐scale data management and handling • Tools and support for automated image analysis of large data sets • Tools and support for data mining and evalua9on tools • Large-‐scale compu9ng (“cluster”) to enable rapid analysis of large data sets
1st Open Call: 25 Jan – 30 Apr 2013
• 1st Call focuses on technologies that will provide physical open access to imaging technologies
• Eligible applicants will be reviewed by general and technology specific review criteria
• Addi9onal imaging technologies will be added in future open calls ajer passing the Euro-‐BioImaging technology iden9fica9on process: 1. Demonstrate user need for (new) imaging technology 2. Develop research infrastructure model for providing open access to
this imaging technology 3. Demonstra9on of feasibility in PCS
Summary Open call for Nodes
To Dos for Node applicants
1. Contact your national imaging community. 2. Talk to your national funders.
3. Submit your Expression of Interest online until April 30th.
Forms and templates will be available on the Euro-BioImaging website on January 25th, 2013.
Webportal
Biological Imaging Jan Ellenberg (Scientific Coordinator) Antje Keppler (Project Manager) [email protected]
Medical Imaging Stefan Schönberg (Scientific Coordinator) Pamela Zolda (Project Manager) [email protected]
www.eurobioimaging.eu